EKTERLY (Sebetralstat) Patent Expiration, LOE Window & CMS Spending

EKTERLY (Sebetralstat) by Kalvista: FDA Orange Book core substance LOE 2039-01-26, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $35,614 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKalvista
FDA Application & PathwayN219301 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-01-26
Last Listed Patent or Exclusivity Date2039-01-26
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($35,614 intro WAC)